MMBiosensing is a biotechnology platform developer that was founded in 2011 by Dr. Amos Danielli to commercialize a novel cardiac biomarker diagnostic technology that brings lab-quality, high-sensitivity detection to the point-of-care.
The management team, including Abu Abraham, Gabe Santa-Cruz, and Robbie Garrison, was formed and incubated by the Hatchery program at Washington University in St. Louis's Olin Business School.
We are developing a point-of-care device which will change the way heart attacks are diagnosed in the Emergency Department by providing high-sensitivity detection of cardiac troponin I (cTnI).
We are actively participating in several startup competitions:
If you are interested in connecting with us, please send us an email.